Often creating new problems that require even more drug-based solutions.

‘Here, we show that disruption of the microbiota impairs the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy,’ create the authors. ‘In antibiotics-treated or germ-free mice, tumor-infiltrating myeloid-derived cells respond poorly to therapy, resulting in lower cytokine creation and tumor necrosis after CpG-oligonucleotide treatment and deficient creation of reactive oxygen species and cytotoxicity after chemotherapy.’ Without healthy gut microbiota, conventional malignancy treatments are worthless In other words, gut flora may actually play a critical part in the enablement of chemotherapy and immune therapies to target cancer cells and get rid of tumors.Application for regulatory authorization of apixaban in European countries to be submitted Bristol-Myers Squibb Firm and Pfizer today announced that the firms are planning to submit an application for regulatory authorization of apixaban in Europe for preventing venous thromboembolism after orthopedic medical procedures in the first half of 2010. The application will be supported by ADVANCE-2 and ADVANCE-3, two scientific trials that evaluated apixaban versus the European dosing regimen of enoxaparin for avoidance of VTE in sufferers undergoing orthopedic surgery. Outcomes of ADVANCE-2 were 1st presented in July 2009 at the 22nd Congress of the International Society on Thrombosis and Haemostasis in Boston.